# What did SURMOUNT-ADOLESCENTS show for tirzepatide in teens?

Published November 17, 2026 · Updated November 17, 2026 · Data as of November 15, 2026

In the SURMOUNT-ADOLESCENTS trial in teens with obesity, [tirzepatide](https://pepbank.io/p/tirzepatide) reduced body mass index (BMI) by 18.5% at week 72. Placebo led to a 0.5% increase. [1] JAMA published the trial on November 15, 2026. [2] In the trial, 79.6% of teens on tirzepatide reached at least a 5% BMI reduction, versus 28.5% on placebo. [1, 2] Serious adverse events occurred in 7.4% of the tirzepatide group and 3.9% of the placebo group. [1]

## Key points

- In the trial, BMI fell by 18.5% with tirzepatide at week 72, compared with a 0.5% increase with placebo. [1]
- At week 72 in the trial, 79.6% of teens on tirzepatide reached at least a 5% BMI reduction, versus 28.5% on placebo. [1, 2]
- Adverse events led 10 teens on tirzepatide (9.3%) to stop treatment in the trial, compared with none on placebo. [1]
- As of November 15, 2026, PepBank holds 360 publications with findings in people for tirzepatide. [3]
- The FDA approved Zepbound in 2023 to reduce and maintain body weight in adults with obesity, or overweight with at least one weight-related condition. [4]

## What did the SURMOUNT-ADOLESCENTS trial find?

In the trial, teens on tirzepatide saw their BMI fall by 18.5% at week 72. Teens on placebo saw a 0.5% increase. [1] In the trial, tirzepatide plus a healthy lifestyle intervention led to significant reductions in percent change in BMI compared with placebo at 72 weeks. [5]

At week 72, 87 of 109 teens on tirzepatide reached at least a 5% BMI reduction, compared with 14 of 51 on placebo. [2] The risk difference between the two groups in the trial was 51.2 percentage points. [1] All 10 key secondary outcomes in the trial favored tirzepatide. [2]

Main results at week 72 in the SURMOUNT-ADOLESCENTS trial

| Measure | Tirzepatide | Placebo |
| --- | --- | --- |
| Change in BMI at week 72 in the trial | 18.5% reduction in the trial | 0.5% increase in the trial [1] |
| At least 5% BMI reduction in the trial | 79.6% of teens in the trial | 28.5% of teens in the trial [1, 2] |
| Teens in the trial with at least 5% BMI reduction | 87 of 109 teens in the trial | 14 of 51 teens in the trial [2] |

Curo, a peptide shop with the same owner as PepBank, has a related article. [Retatrutide vs Tirzepatide vs Semaglutide: How the GLP-1 Class Differs (2026)](https://curo.you/insights/retatrutide-vs-tirzepatide-vs-semaglutide-glp-1-class)

## How was the trial set up?

The trial randomized 160 adolescents with obesity or overweight with obesity-related complications to tirzepatide or placebo. [1, 5] Of these, 109 were randomized to tirzepatide and 51 to placebo. [1] Researchers gave tirzepatide in addition to a healthy lifestyle intervention and compared BMI change at 72 weeks. [5]

The results were presented at the Obesity Society's ObesityWeek 2026 in Washington, DC, on November 15, 2026. [1] JAMA published the trial online the same day. [1, 2]

## What did the trial show about safety?

Serious adverse events occurred in 8 teens on tirzepatide (7.4%) and 2 on placebo (3.9%) during the 72-week treatment period. [1] Adverse events led 10 teens on tirzepatide (9.3%) to stop treatment, compared with none on placebo. [1]

## What did other tirzepatide trials in people find?

In a trial in adults with obesity without diabetes, tirzepatide reduced body weight at week 72 by 15%, 19.5% and 20.9%. Placebo reduced it by 3.1%. [6] In a trial in people with type 2 diabetes and heart disease, [tirzepatide compared with dulaglutide](https://pepbank.io/compare/dulaglutide-vs-tirzepatide) was noninferior for the primary composite end point. [7] In the same group of patients, tirzepatide lowered the risk of the primary composite kidney outcome by 23% versus dulaglutide. [8]

## Where does tirzepatide stand with regulators?

The FDA approved Zepbound in 2023 to reduce and maintain body weight in adults with obesity. [4] The FDA approved Mounjaro in 2022. Its FDA label covers glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes. [9] The EMA approved Mounjaro in the EU in 2022. [10]

For long-term treatment of obesity in adolescents, the FDA has approved orlistat, liraglutide, semaglutide and phentermine-topiramate. [1]

## What does PepBank hold on tirzepatide?

As of November 15, 2026, PepBank holds 378 [tirzepatide studies](https://pepbank.io/p/tirzepatide/studies) where tirzepatide was given. [3] Those studies give PepBank 2165 results for tirzepatide. [3]

- By [evidence class](https://pepbank.io/methods), PepBank holds 360 publications with 2050 findings in people. [3]
- PepBank holds 14 publications with 68 findings in animals. [3]
- PepBank holds 3 publications with 12 laboratory findings in cells or tissue. [3]
- PepBank holds 9 publications with 35 findings predicted by a computer model. [3]
- PepBank holds 254 registered trials that test tirzepatide. [3]

## FAQ

### What is tirzepatide approved for in the US?

The FDA approved Zepbound in 2023 to reduce and maintain body weight in adults with obesity, or overweight with at least one weight-related condition. [4] The FDA approved Mounjaro in 2022. Its FDA label covers glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes. [9] For adolescents with obesity, the FDA has approved orlistat, liraglutide, semaglutide and phentermine-topiramate. [1]

### How many teens took part in SURMOUNT-ADOLESCENTS?

The SURMOUNT-ADOLESCENTS trial randomized 160 participants. Of these, 109 were randomized to tirzepatide and 51 to placebo. [1] The trial ran in adolescents with obesity or overweight with obesity-related complications. Researchers gave tirzepatide in addition to a healthy lifestyle intervention. [5] At week 72 in the trial, 87 of 109 teens on tirzepatide reached at least a 5% BMI reduction. On placebo, 14 of 51 teens reached it. [2]

### When were the SURMOUNT-ADOLESCENTS results published?

JAMA published the SURMOUNT-ADOLESCENTS trial online on November 15, 2026. [2] The results were presented the same day at the Obesity Society's ObesityWeek 2026 in Washington, DC. [1, 2] JAMA Network said it was publishing two clinical trials and its fourth JAMA Summit Report at ObesityWeek. [5]

## Sources

1. Tirzepatide in Adolescents With Obesity: The SURMOUNT-ADOLESCENTS Randomized Clinical Trial | Obesity | JAMA. jamanetwork.com, 2026-11-15. https://jamanetwork.com/journals/jama/fullarticle/2856796
2. Tirzepatide in Adolescents With Obesity: Research Summary | Obesity | JAMA. jamanetwork.com, 2026-11-15. https://jamanetwork.com/journals/jama/fullarticle/2856794
3. Tirzepatide in PepBank. PepBank, 2026-11-15. https://pepbank.io/p/tirzepatide
4. Zepbound (US). DailyMed (U.S. National Library of Medicine), 2026-10-09. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
5. Tirzepatide in Adolescents With Obesity. media.jamanetwork.com, 2026-11-15. https://media.jamanetwork.com/media-releases/10.1001/jama.2026.23420
6. Tirzepatide Once Weekly for the Treatment of Obesity. The New England journal of medicine, 2022-06-04. https://pubmed.ncbi.nlm.nih.gov/35658024/ PMID 35658024. Evidence class: human.
7. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. The New England journal of medicine, 2025-12-01. https://pubmed.ncbi.nlm.nih.gov/41406444/ PMID 41406444. Evidence class: human.
8. A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial. The lancet. Diabetes & endocrinology, 2026-05-11. https://pubmed.ncbi.nlm.nih.gov/42114520/ PMID 42114520. Evidence class: human.
9. Mounjaro (US). DailyMed (U.S. National Library of Medicine), 2026-10-09. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
10. Mounjaro (EU). European Medicines Agency, 2026-10-09. https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro

How this article is made: PepBank writes its articles from the studies and records in its database. Each claim links to its source. [Read how PepBank collects and classes evidence.](https://pepbank.io/methods)

Canonical: https://pepbank.io/blog/what-did-surmount-adolescents-show-for-tirzepatide-in-teens

This is not medical advice.
